OPRM1 and Alzheimer disease: Ourfinding of an increased PIT effect in relapsing AD G+ carriers might also berelevant for precision medicine, particularly in the light of the ongoingdiscussion of the OPRM1 polymorphism as a potential biomarkerfor the effectiveness of naltrexone treatment (Chamorro et al., 2012; Hartwell et al., 2020;Oslin et al.,2003; Setiawan etal., 2012; Ziauddeen et al., 2016).